UNSPSC 51351904: Gestrinone

This classification denotes a therapeutic progestin with the molecular formula C21H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1421533RCM, chemically known as 18,19-dinorpregna-4,9,11-trien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)- (9ci) but generally known as gestrinone, which bears US NIH Compound Identifier 27812. European Medicines Agency schedules Gestrinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13963MIG. The term GESTRINONE is an International Non-Proprietary Name.

UNSPSC 51351904 Gestrinone is a Commodity code for a specific pharmaceutical agent used in endometriosis treatment. State and local governments procure gestrinone primarily through health departments, public health clinics, correctional facilities, and hospital systems that serve indigent or uninsured populations. The drug is typically sourced as part of broader pharmaceutical supply contracts or specialty medication formularies managed by state Medicaid programs, public health authorities, and county health systems. Purchases reflect both routine clinic inventory and episodic demand driven by patient enrollment in endometriosis management programs.

The recent-opportunities block contains no records of state or local gestrinone solicitations. Without posted RFP, RFQ, IFB, or ITB notices tied to this code in the current period, there is no actionable intelligence on geographic concentration, issuing-body frequency, or near-term procurement volume to report.